172 related articles for article (PubMed ID: 10864338)
1. Current national health insurance coverage policies for breast and ovarian cancer prophylactic surgery.
Kuerer HM; Hwang ES; Anthony JP; Dudley RA; Crawford B; Aubry WM; Esserman LJ
Ann Surg Oncol; 2000 Jun; 7(5):325-32. PubMed ID: 10864338
[TBL] [Abstract][Full Text] [Related]
2. Current national health insurance policies for thyroid cancer prophylactic surgery in the United States.
Dackiw AP; Kuerer HM; Clark OH
World J Surg; 2002 Aug; 26(8):903-6. PubMed ID: 12045864
[TBL] [Abstract][Full Text] [Related]
3. Insurance policies for prophylactic surgery: to cover or not to cover?
Morrow M
Ann Surg Oncol; 2000 Jun; 7(5):321-2. PubMed ID: 10864336
[No Abstract] [Full Text] [Related]
4. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients.
Grann VR; Panageas KS; Whang W; Antman KH; Neugut AI
J Clin Oncol; 1998 Mar; 16(3):979-85. PubMed ID: 9508180
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.
Anderson K; Jacobson JS; Heitjan DF; Zivin JG; Hershman D; Neugut AI; Grann VR
Ann Intern Med; 2006 Mar; 144(6):397-406. PubMed ID: 16549852
[TBL] [Abstract][Full Text] [Related]
6. Insurance reimbursement for risk-reducing mastectomy and oophorectomy in women with BRCA1 or BRCA2 mutations.
Kauff ND; Scheuer L; Robson ME; Glogowski E; Kelly B; Barakat R; Heerdt A; Borgen PI; Davis JG; Offit K
Genet Med; 2001; 3(6):422-5. PubMed ID: 11715007
[TBL] [Abstract][Full Text] [Related]
7. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer EJ; Verhoog LC; Brekelmans CT; Seynaeve C; Tilanus-Linthorst MM; Wagner A; Dukel L; Devilee P; van den Ouweland AM; van Geel AN; Klijn JG
Lancet; 2000 Jun; 355(9220):2015-20. PubMed ID: 10885351
[TBL] [Abstract][Full Text] [Related]
8. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
9. Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations.
Schrag D; Kuntz KM; Garber JE; Weeks JC
N Engl J Med; 1997 May; 336(20):1465-71. PubMed ID: 9148160
[TBL] [Abstract][Full Text] [Related]
10. Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Familial Breast Cancer Collaborative Group.
Vasen HF; Haites NE; Evans DG; Steel CM; Møller P; Hodgson S; Eccles D; Morrison P; Stoppa Lyonet D; Chang-Claude J; Caligo M
Eur J Cancer; 1998 Nov; 34(12):1922-6. PubMed ID: 10023316
[TBL] [Abstract][Full Text] [Related]
11. Insurance policies for prophylactic mastectomy: to cover or not to cover?
Piver MS
Ann Surg Oncol; 2000 Oct; 7(9):714. PubMed ID: 11034252
[No Abstract] [Full Text] [Related]
12. Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
Yamauchi H; Nakagawa C; Kobayashi M; Kobayashi Y; Mano T; Nakamura S; Arai M
Breast Cancer; 2018 Mar; 25(2):141-150. PubMed ID: 29019095
[TBL] [Abstract][Full Text] [Related]
13. Breast Cancer Risk Reduction Decisions of the BRCA-Positive Patient: An Observational Study at a Single Institution.
Johns D; Agarwal J; Anderson L; Ying J; Kohlmann W
J Womens Health (Larchmt); 2017 Jun; 26(6):702-706. PubMed ID: 27922795
[TBL] [Abstract][Full Text] [Related]
14. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.
Burke W; Daly M; Garber J; Botkin J; Kahn MJ; Lynch P; McTiernan A; Offit K; Perlman J; Petersen G; Thomson E; Varricchio C
JAMA; 1997 Mar; 277(12):997-1003. PubMed ID: 9091675
[TBL] [Abstract][Full Text] [Related]
15. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
[TBL] [Abstract][Full Text] [Related]
16. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.
Grann VR; Jacobson JS; Whang W; Hershman D; Heitjan DF; Antman KH; Neugut AI
Cancer J Sci Am; 2000; 6(1):13-20. PubMed ID: 10696733
[TBL] [Abstract][Full Text] [Related]
17. Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy.
van Roosmalen MS; Verhoef LC; Stalmeier PF; Hoogerbrugge N; van Daal WA
J Clin Oncol; 2002 Apr; 20(8):2092-100. PubMed ID: 11956270
[TBL] [Abstract][Full Text] [Related]
18. What would you do? Specialists' perspectives on cancer genetic testing, prophylactic surgery, and insurance discrimination.
Matloff ET; Shappell H; Brierley K; Bernhardt BA; McKinnon W; Peshkin BN
J Clin Oncol; 2000 Jun; 18(12):2484-92. PubMed ID: 10856109
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes.
Lerman C; Narod S; Schulman K; Hughes C; Gomez-Caminero A; Bonney G; Gold K; Trock B; Main D; Lynch J; Fulmore C; Snyder C; Lemon SJ; Conway T; Tonin P; Lenoir G; Lynch H
JAMA; 1996 Jun; 275(24):1885-92. PubMed ID: 8648868
[TBL] [Abstract][Full Text] [Related]
20. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations.
Schrag D; Kuntz KM; Garber JE; Weeks JC
JAMA; 2000 Feb; 283(5):617-24. PubMed ID: 10665701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
